Clinical Trials Logo

Muscular Dystrophies clinical trials

View clinical trials related to Muscular Dystrophies.

Filter by:

NCT ID: NCT02056808 Completed - Clinical trials for Duchenne Muscular Dystrophy

A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

Start date: November 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether increasing doses of SMT C1100 are safe, well tolerated and achieve appropriate blood levels in patients with Duchenne Muscular Dystrophy (DMD).

NCT ID: NCT02050776 Withdrawn - Clinical trials for Limb Girdle Muscular Dystrophy

Stem Cell Therapy in Limb Girdle Muscular Dystrophy

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study was to study the effect of stem cell therapy on the course of the disease in patients with Limb Girdle Muscular Dystrophy.

NCT ID: NCT02036463 Withdrawn - Clinical trials for Duchenne Muscular Dystrophy (DMD)

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Start date: November 2014
Phase: Phase 2
Study type: Interventional

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease for which no curative treatment has yet been identified, making it important to slow progression and improve the quality of life among affected boys and young men. Treatment with corticosteroids is standard of care for patients with DMD five years old and older, due to the robust observation that this intervention lengthens the interval prior to loss of ambulation but is associated with many side effects. This clinical trial will be conducted in the youngest age group able to receive corticosteroids orally and on whom study outcomes are measurable, ages 3 to 7 years. This is a randomized, double blinded, double masked, placebo-controlled clinical trial that will explore whether better synchronization of corticosteroid administration with the circadian rhythm will provide improved tolerability and at least comparable efficacy to current standards in which corticosteroids are always given in the morning. Furthermore, the trial provides a unique opportunity to rigorously evaluate corticosteroid effects in the young DMD patient, both for efficacy as compared to placebo and as a study of the impact of corticosteroid chronotherapy, or delayed release, on increased tolerability over standard therapy. The main hypothesis is that synchronization of the timing of corticosteroid dosing will improve medication tolerability in children, while maintaining (non-inferiority) the efficacy of corticosteroid. The study also offers a unique opportunity to measure several biomarkers as well as novel genetic modifiers that may further impact the response to corticosteroid in DMD.

NCT ID: NCT02034305 Completed - Clinical trials for Duchenne Muscular Dystrophy

Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy

Start date: January 2014
Phase:
Study type: Observational

This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP ,SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.

NCT ID: NCT02032979 Completed - Clinical trials for Muscular Dystrophy, Facioscapulohumeral

Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2

Start date: October 20, 2014
Phase: N/A
Study type: Interventional

The investigators propose to conduct a comparative pilot cognitive and psychiatric profiles of 10 patients Facio-Scapulo-Humeral Dystrophy (= FHSD) type 1 and 10 patients with type 2 FSHD study. For this, the investigators relied on observational components: FSHD2 patients appear more often present with psychiatric comorbidities and seem to have lower cognitive performance compared to FSHD1 patients. This was confirmed by a preliminary study on a small sample population of patients. It seems to exist mainly executive dysfunction associated with attention disorders in patients FSHD2. Moreover, their performance in IQ tests would be low in relation to their socio-educational and compared with patients FSHD1 level.

NCT ID: NCT02018731 Completed - Clinical trials for Becker's Muscular Dystrophy (BMD)

L-citrulline and Metformin in Becker's Muscular Dystrophy

Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of the study is to compare the effects of L-citrulline and metformin and their combination therapy on muscle function and force in patients with Becker muscular dystrophy (BMD).

NCT ID: NCT02015481 Completed - Clinical trials for Oculopharyngeal Muscular Dystrophy

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

HOPEMD
Start date: February 2014
Phase: Phase 2
Study type: Interventional

The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.

NCT ID: NCT01999075 Completed - Clinical trials for Duchenne Muscular Dystrophy

Stacking Exercises Aid the Decline in FVC and Sick Time

STEADFAST
Start date: March 2013
Phase: Phase 4
Study type: Interventional

Duchenne Muscular Dystrophy is complicated by weak breathing muscles and lung infections. "Lung volume recruitment" is a technique performed using a face mask or mouthpiece and a hand-held resuscitation bag to stack breaths, inflate the lungs and help clear the airways of secretions by increasing the forcefulness of a cough. We believe this will slow down the steady loss of lung function, prevent lung infection, and improve quality of life. Our aim is to compare the outcome of a group of individuals with DMD treated with standard care to another group that also receives lung volume recruitment. If effective, this study will change clinical practice by including twice-daily treatment as part of the standard of care for individuals with DMD, in order to improve their lung health and quality of life.

NCT ID: NCT01995032 Completed - Clinical trials for Duchenne's Muscular Dystrophy (DMD)

L-citrulline and Metformin in Duchenne's Muscular Dystrophy

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of the study is to show that the intake of L-citrulline and metformin improves muscle function and delay of progression in patients with Duchenne's muscular dystrophy.

NCT ID: NCT01990976 Completed - Muscular Dystrophy Clinical Trials

Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.

FSHD3
Start date: May 2012
Phase: N/A
Study type: Observational

The safety of guided practice of physical activity in myopathies is increasingly accepted, including muscular dystrophies. In facioscapulohumeral dystrophy (FSHD), one of the most common muscular dystrophy, the aerobic training showed its physiological and functional efficiency without affecting the quality of life of patients. The issue of exercise therapy extended to all neuromuscular diseases, as has been rigorously analyzed, shows that the use of a training program combining endurance exercise targeted exercises and strength is even more relevant. To complete the multidimensional assessments be managed by each team ( physiological assessments, functional tissue and quality of life) it is relevant to continue , for a descriptive study quantitative and qualitative analyzes by muscle imaging and spectroscopy (MRI and Nuclear Resonance Imaging (NMR) spectroscopy ).